Supplementary Figure S2 from Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer

Figure S2 A. Bulk RNA-sequencing data from MOC22 tumors harvested on day 17, and MOC1 and MOC1-esc1 tumors harvested on day 14 post implantation are shown for indicated genes as z-score. (n=3 for each model.) B. qPCR data of Xcr1 from in vivo established tumors harvested on day 12 post-inoculation. n=16, pooled data from two independent experiments. C. Bulk RNA-seq data of indicated genes in pretreatment tumor samples from patients who received subsequent aPD1 therapy shown as z-score. “NK signature” represents the average z-score of GNLY, KLRC3, KLRD1, KLRF1, and NCR1 (10). (n=8 responders, n=15 non-responders.) D, E. Flow cytometric analysis of MOC22, MOC1P and MOC1esc1 tumors harvested on day 12 post-inoculation. (n=8 tumors each, representative data of two independent experiments.) F, G. Representative gating strategies for T and NK cells (F) and DCs (G) used throughout the paper